PR Newswire (Fri, 8:00AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
12,394 people get ARNA articles and Market Currents by email alert.
Get email alerts on ARNA »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
PR Newswire (May 10, 2013)
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
Arena's CEO Discusses Q3 2012 Results - Earnings Call TranscriptTue, Nov 6, 2012 • 10 Comments
-
Arena Pharmaceuticals Inc. Q3 2009 Earnings Call TranscriptTue, Nov 10, 2009
-
Arena Pharmaceuticals, Inc. Q4 2008 Earnings Call TranscriptFri, Mar 13, 2009
-
Arena Pharmaceuticals, Inc. Q3 2008 Earnings Call TranscriptThu, Oct 30, 2008
-
Arena Pharmaceuticals Inc. Q2 2008 Earnings Call TranscriptTue, Aug 5, 2008
-
Arena Pharmaceuticals, Inc. Q1 2008 Earnings Call TranscriptWed, May 7, 2008 • 1 Comment
-
Arena Pharmaceuticals Q4 2007 Earnings Call TranscriptMon, Mar 10, 2008
-
Arena Pharmaceuticals Q3 2007 Earnings Call TranscriptWed, Oct 17, 2007
-
PR Newswire (Fri, 8:00AM)
-
PR Newswire (May 10, 2013)
-
at CNBC.com (May 2, 2013)
-
PR Newswire (May 2, 2013)
-
at CNBC.com (Apr 11, 2013)
-
PR Newswire (Apr 5, 2013)
-
at MarketWatch.com (Mar 4, 2013)
-
PR Newswire (Feb 27, 2013)
-
PR Newswire (Feb 6, 2013)
-
at CNBC.com (Feb 5, 2013)
-
PR Newswire (Jan 2, 2013)
-
at CNBC.com (Dec 17, 2012)
-
at MarketWatch.com (Dec 14, 2012)
-
PR Newswire (Dec 6, 2012)
ARNA vs. ETF Alternatives
Company Description
We are a clinical-stage biopharmaceutical company committed to discovering and developing innovative therapies offering significant medical advances and new options for patients. We are focused on discovering, developing and commercializing oral drugs in four major therapeutic areas:... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, February 25, 2:45 PM Arena Pharmaceutical (ARNA +1.4%) trades in the green today after earlier disclosing the price for a 60-day supply of Belviq 10-mg tablets at $199.50. This compares with Vivus' (VVUS +1%) Qsymia, which retails for $160 per month at a medium dose and $220 per month for the higher dose. Analysts note the success of Belviq will largely depend on lower co-payments and broader insurance coverage, which could come in the next two years. 5 Comments [Healthcare, On the Move]
- Wednesday, February 6, 12:20 PM Shares of Arena Pharmaceutical (ARNA +1.8%) and Vivus (VVUS +3.3%) both gain today, after Leerink Swann resumes coverage on both with an Outperform rating. The firm gives VVUS a price target range of $19 - $20. 2 Comments [Healthcare, On the Move]
-
Tuesday, January 22, 12:45 PM
Midday top 10 gainers: PBIB +32%. DQ +18%. TECUA +18%. ONP +17%. USEG +17%. RDCM +17%. CIMT +14%. BOX +14%. MTRX +12%. PRCP +12%.
Midday top 10 Losers: CALI -12%. OIBR -12%. BVX -10%. DOM -9%. ARNA -8%. IIVI -8%. AMRI -8%. UPI -8%. IPXL -8%. EXFO -7%. Comment! [On the Move] - Tuesday, January 22, 9:43 AM Arena Pharmaceuticals (ARNA) slides 7.8% and adds to a 6.5% loss on Friday after the EU's CHMP health regulator didn't make a decision about approving the company's Belviq weight-loss treatment at meetings last week, meaning the firm will have to wait for at least another month for a ruling. It doesn't help that Arena received a 180-day list of questions about Belviq. "It's not pretty," says Adam Feuerstein. (Arena 8-K) 3 Comments [On the Move, Healthcare]
-
Tuesday, January 22, 9:10 AM
Premarket gainers: BOX +13%. CLSN +11%. EBR +8%. RIMM +7%.
Losers: OIBR -11%. ARNA -7%. JW.A -5%.
Comment! [On the Move] - Wednesday, January 2, 9:44 AM The Street's Adam Feuerstein makes 13 biotech stock predictions for 2013, with his number one being that the U.S. launch of Arena Pharmaceuticals' (ARNA) and Eisai's weight-loss pill Belviq "will be a major disappointment." Feuerstein also reckons that Belviq will fail to receive European approval. 17 Comments [Healthcare]
- Monday, December 24, 2012, 7:27 AM The marketing partner (Eisai ESALY.PK) for Arena's (ARNA) obesity-fighting Belviq has petitioned the DEA to expedite its approval process. If granted (this sort of request is rarely denied), this could have the drug in pharmacies on February 7, writes Joe Dedvukaj. Combined with what looks to be imminent EU approval, Street analysts will find themselves needing to catch up to lofty sales figures. 3 Comments [Healthcare, Quick Ideas]
- Wednesday, November 28, 2012, 1:52 PM Arena Pharmaceuticals (ARNA -0.1%) enters into a co-development and license agreement with Ildong Pharmaceutical for Temanogrel, ARNA's treatment for for myocardial infarction, acute coronary syndrome, stroke, peripheral artery disease, and other cardiovascular diseases, subject to the drug's further development and regulatory approval. The agreement grants Ildong exclusive rights to commercialize and market the drug. 7 Comments [Healthcare, Global & FX]
- Wednesday, November 21, 2012, 10:40 AM Weight loss drug makers get a lift today after Aetna (AET -0.6%) revises its criteria under which the insurer considers weight reduction medications as "medically necessary" for treatment of obesity. In a Clinical Policy Bulletin revision dated yesterday, AET identified certain medications that have been approved by the FDA for weight reduction which would be covered under its policy: Qsymia, marketed by VIVUS (VVUS +13.2%), Belviq from Arena Pharmaceuticals (ARNA +2.9%), Didrex from Pfizer (PFE +0.1%), Xenical from Roche (RHHBY +0.3) and GlaxoSmithKline's (GSK +0.2%) Alli. Orexigen (OREX +6.5%), although not named in the bulletin, is also higher on the news. 11 Comments [Healthcare, On the Move]
- Tuesday, November 6, 2012, 4:38 PM More on Arena Pharmaceuticals (ARNA): Q3 beats on a per share basis but comes up short on revenue. Separately, the company announced that it had granted Ildong Pharmaceutical exclusive rights to market and distribute its weight-loss drug Belviq in South Korea, subject to regulatory approval of BELVIQ by the Korea Food and Drug Administration. Shares +1.6% AH. 8 Comments [Earnings, Global & FX, On the Move]
- Tuesday, November 6, 2012, 4:17 PM Arena Pharmaceutical (ARNA): Q3 EPS loss of -$0.07 beats by $0.02. Revenue of $1.5M (-57% Y/Y) misses by $2M. Shares +1.71% AH. (PR) 6 Comments [Healthcare, Earnings]
- Tuesday, November 6, 2012, 12:10 AM Notable earnings after Tuesday’s close: AMRS, ARNA, DPM, EXXI, EZPW, GPOR, GTE, NWSA, RAX, RBCN, REXX, SGY, STEC, TWO Comment! [Earnings]
- Monday, November 5, 2012, 5:35 PM Notable earnings after Tuesday’s close: AMRS, ARNA, DPM, EXXI, EZPW, GPOR, GTE, NWSA, RAX, RBCN, REXX, SGY, STEC, TWO Comment! [Earnings]
- Monday, September 17, 2012, 11:13 AM Vivus (VVUS +1.3%) moves up today after quietly disclosing in an 8-K with the SEC disclosing that its weight-loss drug Qsymia was available in the U.S. market. The announcement was also made on its website, Qsymia.com. Peer competitor Arena Pharmaceuticals (ARNA +1%) also gets a lift on the news, in spite of the fact that its weight-loss drug, Belviq, won't be available until 2013. 7 Comments [Healthcare, On the Move]
- Thursday, September 6, 2012, 3:54 PM Shares of Orexigen (OREX +16.7%) are soaring after Credit Suisse initiates coverage with an Outperform, saying it likes the prospects of a trial that will look at the cardiovascular impact of Contrave. Leerink Swann also recommends investors buy it aggressively. Meanwhile, it starts Arena Pharmaceutical (ARNA -4.6%) with an Underperform , saying Belviq may not generate enough revenue to justify the stock's current valuation. 22 Comments [Healthcare, On the Move]
- Tuesday, August 28, 2012, 10:44 AM Short sellers continue to bet on biotech firms compared to the July 31 settlement date. Arena Pharmaceuticals (ARNA -0.3%), Gilead Sciences (GILD +1.4%), Pharmacyclics (PCYC -2.2%), Vertex Pharmaceuticals (VRTX -0.6%) and VIVUS (VVUS -0.4%) all saw short interest rise more than 9% between July 31 and August 15. Two exceptions to the rule worth noting however, are Alexion Pharmaceuticals (ALXN +0.1%) and Biogen Idec (BIIB -0.4%), both of which saw short interest decline by 10% and 8.4%, respectively. 3 Comments [Healthcare]
-
- View all 0 replies
-
- View all 2 replies
-
-
-
Day Trader001
Anyone else wanting to sell $ARNA for $6.80 I have my buy bid's in!! Thanks to the dummy that did..$$$ - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Ryan Mallory
Fuinhaz Setups for April 24 2013 | $AIXG $ARNA $ASML $BMC $BRCM $DGIT $GOLD $NFLX | SharePlanner http://bit.ly/ZkFLxT - View all 0 replies
-
Ryan Mallory
Fuinhaz Setups for April 12 2013 | $ARNA $BBRY $DRTX $NFLX $ZNGA | SharePlanner http://bit.ly/16ZDx6Y - View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
- View all 2 replies
-
slimbobway: Long means hanging in there. Even when it drops cuz it will rise again! Take a chill pill.
-
Chemist357: Rember the bear raid the week of advisory committee? dropped several dollars!!! Thank god I did not have those stupid "stop losses"
-
- View all 3 replies
-
-
garuda11: Naah, it is bound to bounce back! Short strike wouldn't last long though. :)
-
- View all 2 replies
-
-
phemale60: realornot: your day will come -- again -- always does. I think we're both in on the ground floor of something big (no pun intended)!
-
SMaturin
$ARNA - Belviq will get DEA Schedule IV: http://1.usa.gov/Tv8MCa How soon can they get on the market now? - View all 4 replies
-
-
phemale60: By then VVUS's Qsymia will have a lock on the heavies. -- (only kidding) -- good luck to everyone holding ARNA!! Happy Holidays!
-
- View all 1 replies
-
-
Michael Bryant
Novo Nordisk ($NVO) "is testing higher dosages [of its drugs] for use in obesity." Bad news for $ARNA & $VVUS http://bit.ly/VLBRb5 - View all 9 replies
-
-
Chemist357: To take a pill or inject yourself...I think Novo nordisk would have a long way to go. Only purpose extend patent life...
-
- View all 2 replies
-
phemale60: realornot, I could rub it in that VVUS is up nearly 11% today while ARNA up less than 1%, but I won't. You have your good days. :-)
-
-
- View all 17 replies
-
sundate36: AFFX seems to be consolidating as well. It looks like it may break out as well...
-
-
R.S. Analytics
$ARNA $AVNR $AMRN $SRPT....new article: http://tinyurl.com/bz64k3v Lots of trading opportunities coming up!!! - View all 3 replies
-
R.S. Analytics: Good call - I would wait till around $26 to position in. If they release steller 60wk data, with a low float, this could easily hit $75.
-
-
Day Trader001
QVT spanking VVUS for lack of sales...............................They should have bought ARNA - View all 12 replies
-
phemale60: Hi, looks like they left your stocktalk on here but remove mine as fast as I post them. You Rate!! ;-)
-
Day Trader001: No...Minnie zapped'em Lol. They had & still have tech issues after this awful format change.
-
- View all 19 replies
-
-
-
- View all 4 replies
-
-
Day Trader001: Hello Minnie. :) maybe she'll bring us some luck! We have a new little grey one also named Charly. Hoping arna hits at least 9.00 this week
-
rockiemoon
Isn't the weak launch of Qsymia predicted? Check what those who are downgrading and bashing VVUS today were doing a few months ago! Go, ARNA - View all 4 replies
-
rockiemoon: At this level, ARNA is a buy, I sold my second half position a little above 10, will reload some for the coming launch and decision from EU
-
Day Trader001: "Sure it is" I added several thousand shares yesterday and will dump some at 9.00-10.00 and hold the rest
-
- View all 7 replies
-
-
-
Boatyzaffa
buy to open 2,500 ARNA @ 8.65. Going to risk 0.40 cents here to make 1.20, so risking $1,000 for the chance to make $3,000 - View all 64 replies
-
westcoastinvests: The difference between you and Boaty is that he doesn't post when his positions move up the way you do. -
westcoastinvests: My issue is the amount of attention you spend on touting the positions that are up as opposed to talking about the ones that are down